文献速递肝病

KCTD17通过胰高血糖素依赖途径降解PHLPP2促进肝脂肪变性

Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
PubMed 文献 · Gastroenterology · 2017-08-30

研究在小鼠和NAFLD患者肝组织中探索PHLPP2降解机制,发现胰高血糖素经PKA磷酸化PHLPP2促进KCTD17结合并介导泛素化降解,从而增加脂肪生成基因表达和肝脂肪变性,不改变糖异生。

要点

  • 肝细胞PHLPP2缺失延长胰岛素作用信号并诱导肝脂肪变性,但糖耐量正常。
  • 胰高血糖素经PKA磷酸化PHLPP2,促进KCTD17结合并介导其泛素化降解。
  • 肥胖小鼠和NAFLD患者肝组织KCTD17 mRNA升高,敲低KCTD17可减少脂肪生成基因表达。

核心结论

  • 在肥胖小鼠模型中,PHLPP2降解诱导脂肪生成而不影响糖异生。
  • KCTD17在肥胖小鼠和NAFLD患者肝组织中上调,结合磷酸化PHLPP2并靶向其泛素化降解,增加脂肪生成基因表达以促进肝脂肪变性。
  • 作者认为该通路的抑制剂可能被开发用于治疗NAFLD患者。

研究设计与样本

  • 研究分析C57BL/6J对照小鼠、肥胖db/db小鼠和肝特异性PHLPP2缺失小鼠,分别喂食普通饲料或高脂饮食。
  • 研究对PHLPP2缺陷原代肝细胞或CRISPR/Cas9介导的PHLPP2敲除肝癌细胞分析胰岛素信号和基因表达。
  • 研究对转导Ad-HA-Flag-PHLPP2的C57BL/6J小鼠肝组织进行质谱分析,鉴定PHLPP2翻译后修饰及相互作用蛋白。
  • 研究用定量逆转录聚合酶链反应检测不同肝脂肪变性程度患者肝活检组织的mRNA水平。

主要发现

  • PHLPP2敲除肝癌细胞和L-PHLPP2小鼠肝细胞显示胰岛素信号启动正常,但胰岛素作用延长。
  • 普通饲料喂养的L-PHLPP2小鼠糖耐量正常但有肝脂肪变性。
  • 在高脂饮食喂养的C57BL/6J或db/db肥胖小鼠中,内源性PHLPP2被胰高血糖素和PKA依赖的PHLPP2磷酸化(Ser1119和Ser1210)降解,导致PHLPP2与KCTD17结合,后者是Cul3-RING泛素连接酶的底物衔接蛋白。
  • 与健康对照小鼠或无脂肪变性患者肝组织相比,高脂饮食喂养的C57BL/6J或db/db肥胖小鼠肝脏和NAFLD患者肝活检组织中KCTD17 mRNA水平升高。
  • 在原代肝细胞中用短发夹RNA敲低KCTD17增加PHLPP2蛋白但不增加Phlpp2 mRNA,表明KCTD17介导PHLPP2降解。

临床怎么用

  • 原文结论未给出临床推荐。
  • 作者认为该通路的抑制剂可能被开发用于治疗NAFLD患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obesity-induced nonalcoholic fatty liver disease (NAFLD) develops, in part, via excess insulin-stimulated hepatic de novo lipogenesis, which increases, paradoxically, in patients with obesity-induced insulin resistance. Pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) terminates insulin signaling by dephosphorylating Akt; levels of PHLPP2 are reduced in livers from obese mice. We investigated whether loss of hepatic PHLPP2 is sufficient to induce fatty liver in mice, mechanisms of PHLPP2 degradation in fatty liver, and expression of genes that regulate PHLPP2 in livers of patients with NAFLD. METHODS: C57BL/6J mice (controls), obese db/db mice, and mice with liver-specific deletion of PHLPP2 (L-PHLPP2) fed either normal chow or high-fat diet (HFD) were analyzed for metabolic phenotypes, including glucose tolerance and hepatic steatosis. PHLPP2-deficient primary hepatocytes or CRISPR/Cas9-mediated PHLPP2-knockout hepatoma cells were analyzed for insulin signaling and gene expression. We performed mass spectrometry analyses of liver tissues from C57BL/6J mice transduced with Ad-HA-Flag-PHLPP2 to identify posttranslational modifications to PHLPP2 and proteins that interact with PHLPP2. We measured levels of mRNAs by quantitative reverse transcription polymerase chain reaction in liver biopsies from patients with varying degrees of hepatic steatosis. RESULTS: PHLPP2-knockout hepatoma cells and hepatocytes from L-PHLPP2 mice showed normal initiation of insulin signaling, but prolonged insulin action. Chow-fed L-PHLPP2 mice had normal glucose tolerance but hepatic steatosis. In HFD-fed C57BL/6J or db/db obese mice, endogenous PHLPP2 was degraded by glucagon and PKA-dependent phosphorylation of PHLPP2 (at Ser1119 and Ser1210), which led to PHLPP2 binding to potassium channel tetramerization domain containing 17 (KCTD17), a substrate-adaptor for Cul3-RING ubiquitin ligases. Levels of KCTD17 mRNA were increased in livers of HFD-fed C57BL/6J or db/db obese mice and in liver biopsies patients with NAFLD, compared with liver tissues from healthy control mice or patients without steatosis. Knockdown of KCTD17 with small hairpin RNA in primary hepatocytes increased PHLPP2 protein but not Phlpp2 mRNA, indicating that KCTD17 mediates PHLPP2 degradation. KCTD17 knockdown in obese mice prevented PHLPP2 degradation and decreased expression of lipogenic genes. CONCLUSIONS: In mouse models of obesity, we found that PHLPP2 degradation induced lipogenesis without affecting gluconeogenesis. KCTD17, which is up-regulated in liver tissues of obese mice and patients with NAFLD, binds to phosphorylated PHLPP2 to target it for ubiquitin-mediated degradation; this increases expression of genes that regulate lipogenesis to promote hepatic steatosis. Inhibitors of this pathway might be developed for treatment of patients with NAFLD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kim K, Ryu D, Dongiovanni P, et al. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology. 2017. PMID: 28859855. doi:10.1053/j.gastro.2017.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。